Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment
- First Online:
- Cite this article as:
- Selvi, N., Kaymaz, B.T., Şahin, H.H. et al. Mol Biol Rep (2013) 40: 1591. doi:10.1007/s11033-012-2207-6
- 219 Downloads
The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.